Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 3, 2009, Pages 341-352

  Alex, Philip ^a,b   Zachos, Nicholas C ^a   Nguyen, Thuan ^b   Gonzales, Liberty ^b   Chen, Tian E ^a   Conklin, Laurie S ^a   Centola, Michael ^b,c   Li, Xuhang ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^c NONE   (United States)

Author keywords

Cytokines; DSS colitis; Inflammatory bowel disease; Multiplex ELISA; TNBS colitis

Indexed keywords

CHEMOKINE; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 6; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; DEXTRAN SULFATE; PEROXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISCRIMINANT ANALYSIS; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; KILLER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; TH1 CELL; TH17 CELL; TH2 CELL; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS;

ANIMALS; BLOTTING, WESTERN; CHRONIC DISEASE; COLITIS; CYTOKINES; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEROXIDASE; TRINITROBENZENESULFONIC ACID;

EID: 66149137296     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20753     Document Type: Article

References (60)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
3. Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol Rev. 2005;206:277-295.
4. Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005; 206:260-276.
5. Pizarro TT, Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med. 2007;58:433-444.
6. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest. 2007;117:514-521.
7. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
8. Wirtz S, Neufert C, Weigmann B, et al. Chemically induced mouse models of intestinal inflammation. Nat Protoc. 2007;2:541-546.
9. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol. 2008;43:1-17.
10. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694-702.
11. Carvalho FA, Barnich N, Sauvanet P, et al. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm Bowel Dis. 2008;14:1051-1060.
12. Deger C, Erbil Y, Giris M, et al. The effect of glutamine on pancreatic damage in TNBS-induced colitis. Dig Dis Sci. 2006;51:1841-1846.
13. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477-487.
14. Ihle JN. Cytokine receptor signalling. Nature. 1995;377:591-594.
15. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4e lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
16. Fort M, Lesley R, Davidson N, et al. IL-4 exacerbates disease in a Th1 cell transfer model of colitis. J Immunol. 2001;166:2793-2800.
17. Gor DO, Rose NR, Greenspan NS. TH1-TH2: a procrustean paradigm. Nat Immunol. 2003;4:503-505.
18. Tsukada Y, Nakamura T, Iimura M, et al. Cytokine profile in colonic mucosa of ulcerative colitis correlates with disease activity and response to granulocytapheresis. Am J Gastroenterol. 2002;97:2820-2828.
19. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006;116:1310-1316.
20. Scheiffele F, Fuss IJ. Induction of TNBS colitis in mice. Curr Protoc Immunol. 2002;Chapter 15:Unit 15 19.
21. te Velde AA, Verstege MI, Hommes DW. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm Bowel Dis. 2006;12:995-999.
22. Fichtner-Feigl S, Fuss IJ, Preiss JC, et al. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin Invest. 2005;115:3057-3071.
23. Cooper HS, Murthy SN, Shah RS, et al. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993; 69:238-249.
24. Obermeier F, Kojouharoff G, Hans W, et al. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin Exp Immunol. 1999;116:238-245.
25. Chin KW, Barrett KE. Mast cells are not essential to inflammation in murine model of colitis. Dig Dis Sci. 1994;39:513-525.
26. Alex P, Szodoray P, Arthur E, et al. Influence of intraarticular cortico-steroid administration on serum cytokines in rheumatoid arthritis. Clin Rheumatol. 2007;26:845-848.
27. Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:584-592.
28. Szodoray P, Alex P, Chappell-Woodward CM, et al. Circulating cytokines in Norwegian patients with psoriatic arthritis determined by a multiplex cytokine array system. Rheumatology (Oxford). 2007;46:417-425.
29. Jarvis JN, Dozmorov I, Jiang K, et al. Novel approaches to gene expression analysis of active polyarticular juvenile rheumatoid arthritis. Arthritis Res Ther. 2004;6:R15-R32.
30. Li X, Galli T, Leu S, et al. Nae-He exchanger 3 (NHE3) is present in lipid rafts in the rabbit ileal brush border: a role for rafts in trafficking and rapid stimulation of NHE3. J Physiol. 2001;537:537-552.
31. Li X, Zhang H, Cheong A, et al. Carbachol regulation of rabbit ileal brush border Na+-H+ exchanger 3 (NHE3) occurs through changes in NHE3 trafficking and complex formation and is Src dependent. J Physiol. 2004;556:791-804.
32. Neurath MF. IL-23: a master regulator in Crohn disease. Nat Med. 2007;13:26-28.
33. Li X, Conklin LS, Alex P. New serological biomarkers of inflammatory bowel disease. World J Gastroenterol. 2008 (in press).
34. Nakamura RM, Barry M. Serologic markers in inflammatory bowel disease (IBD). MLO Med Lab Obs. 2001;33:8-15; quiz 16-19.
35. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385.
36. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426-431.
37. Alex P, Gucek M, Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis. 2008 (in press).
38. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670-1689.
39. Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19:225-234.
40. Kitajima S, Takuma S, Morimoto M. Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim. 1999;48:137-143.
41. Kullmann F, Messmann H, Alt M, et al. Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int J Colorectal Dis. 2001;16:238-246.
42. Veny M, Closa D, Esteller M, et al. Th17 and Th1 effector responses in Crohn's disease. Gastroenterology. 2008; DDW Oral Presentation.
43. Elson CO, Cong Y, Weaver CT, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007;132:2359-2370.
44. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice. J Exp Med. 1995;182: 1281-1290.
45. Zimmerman NP, Vongsa RA, Wendt MK, et al. Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis. 2008;14: 1000-1011.
46. Pender SL, Chance V, Whiting CV, et al. Systemic administration of the chemokine macrophage inflammatory protein 1alpha exacerbates inflammatory bowel disease in a mouse model. Gut. 2005;54:1114-1120.
47. Tsuchiya T, Fukuda S, Hamada H, et al. Role of gamma delta T cells in the inflammatory response of experimental colitis mice. J Immunol. 2003;171:5507-5513.
48. Gupta N, Bostrom AG, Kirschner BS, et al. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics. 2007;120:e1418-1425.
49. Saluz HP, Jiricny J, Jost JP. Genomic sequencing reveals a positive correlation between the kinetics of strand-specific DNA demethylation of the overlapping estradiol/glucocorticoid-receptor binding sites and the rate of avian vitellogenin mRNA synthesis. Proc Natl Acad Sci U S A. 1986;83:7167-7171.
50. Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom. 2004;61:35-39.
51. Kellar KL, Kalwar RR, Dubois KA, et al. Multiplexed fluorescent bead-based immunoassays for quantitation of human cytokines in serum and culture supernatants. Cytometry. 2001;45:27-36.
52. Djoba Siawaya JF, Roberts T, Babb C, et al. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS ONE. 2008; 3:e2535.
53. Dehqanzada ZA, Storrer CE, Hueman MT, et al. Assessing serum cytokine profiles in breast cancer patients receiving a HER2/neu vaccine using Luminex technology. Oncol Rep. 2007;17:687-694.
54. Funding M, Hansen TK, Gjedsted J, et al. Simultaneous quantification of 17 immune mediators in aqueous humour from patients with corneal rejection. Acta Ophthalmol Scand. 2006;84:759-765.
55. Hoffmann TK, Sonkoly E, Homey B, et al. Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck. Head Neck. 2007;29:472-478.
56. Kofoed K, Schneider UV, Scheel T, et al. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem. 2006;52:1284-1293.
57. Seoane E, Resino S, Micheloud D, et al. Lipid and apoprotein profile in HIV-1-infected patients after CD4-guided treatment interruption. J Acquir Immune Defic Syndr. 2008 (in press).
58. de Jager W, te Velthuis H, Prakken BJ, et al. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003;10:133-139.
59. dupont NC, Wang K, Wadhwa PD, et al. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol. 2005;66:175-191.
60. Alex P, Zachos NC, Conklin LS, et al. Distinct cytokine patterns as effective indicators of disease activity and severity in IBD. Gastroenterology. 2008;134:A204-A204.